Aspen Neuroscience, Inc. Form S-1/A — Oct 22, 2026
Aspen Neuroscience filed Amendment No. 1 to its S-1 for an IPO on Nasdaq under symbol ASPE, with Leerink Partners and UBS Investment Bank leading a five-bank underwriting syndicate. Pricing terms, share count, and proceeds remain blank pending marketing; a to-be-determined reverse stock split is contemplated. The clinical-stage biotech is developing sasineprocel, an autologous iPSC-derived cell therapy for Parkinson's disease.
Key figures
- Total Assets
- 110275000
- Cash Position
- 72377000
- Shares Outstanding
- 194712305
- Pd patients us
- more than one million
- Total liabilities
- 22540000
- Pd patients global
- more than 10 million
- Rd expense h1 2026
- 28454000
- Patients dosed aspiro
- 15
- Proceeds raised to date
- $347 million
- Option weighted avg price
- 0.68
- Stock options outstanding
- 30078745
- Preferred conversion shares
- 177593856
- Treatment emergent adverse events
- 72
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.